The administration of pirfenidone modifies the expression of JMJD2B in a murine model of NASH
Introduction and Objectives: This study aimed to evaluate how the administration of pirfenidone modifies the expression of JMJD2B in a murine model of NASH. Materials and methods: 4–5-week-old male C57BL/6J mice fed a high-fat diet for 16 weeks. Follow-up was done at 4, 8, 12 and 16 weeks. Serum glu...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | Annals of Hepatology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S166526812200196X |
| _version_ | 1797987807802687488 |
|---|---|
| author | JS Rodriguez Sanabria J García Bañuelos R Escutia Gutiérrez CA Monraz Méndez A Santos J Armendáriz-Borunda AS Sandoval Rodríguez |
| author_facet | JS Rodriguez Sanabria J García Bañuelos R Escutia Gutiérrez CA Monraz Méndez A Santos J Armendáriz-Borunda AS Sandoval Rodríguez |
| author_sort | JS Rodriguez Sanabria |
| collection | DOAJ |
| description | Introduction and Objectives: This study aimed to evaluate how the administration of pirfenidone modifies the expression of JMJD2B in a murine model of NASH. Materials and methods: 4–5-week-old male C57BL/6J mice fed a high-fat diet for 16 weeks. Follow-up was done at 4, 8, 12 and 16 weeks. Serum glucose, animal weight, caloric intake, AST, ALT, TAG, Chol and VLDL were measured. The liver was weighed, as was the epididymal adipose tissue. Masson's trichrome hematoxylin-eosin staining was performed. Dual-channel microarrays were hybridized to the 22,000-gene version of the Mus musculus genome. Analyzed with adjusted P-values of <0.05 and Z-score values of >1.5 and <1.5 considered significant. Quantitative variables were analyzed with ANOVA, Tukey for parametric data, and Kruskal-Wallis for non-parametric data. The trial was approved by the research ethics committee. Results: The animals achieved the body and biochemical parameters that demonstrate the development of NASH. The genes involved in epigenetic processes responsible for the development of NASH (SIRT1, SIRT2, JMJD1B) and, in particular, in JMJD2B; which found to have significantly different between the HFD vs. HFP and HFD vs. ND groups. Discussion: JMJD2B is a histone methylation modulating enzyme, implicated in the development of NASH. In our trial, pirfenidone modulates the expression of JMJD2B, helping the recovery of liver function through epigenetic regulation in a murine model of NASH. Conclusion: Pirfenidone appears to modulate epigenetic factors, supporting recovery from the disease. Funding: The resources used in this study were from the hospital without any additional financing Declaration of interest: The authors declare no potential conflicts of interest. |
| first_indexed | 2024-04-11T07:54:04Z |
| format | Article |
| id | doaj.art-b98c9923ca47439ba10414ddf1943fa2 |
| institution | Directory Open Access Journal |
| issn | 1665-2681 |
| language | English |
| last_indexed | 2024-04-11T07:54:04Z |
| publishDate | 2022-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Annals of Hepatology |
| spelling | doaj.art-b98c9923ca47439ba10414ddf1943fa22022-12-22T04:36:00ZengElsevierAnnals of Hepatology1665-26812022-12-0127100854The administration of pirfenidone modifies the expression of JMJD2B in a murine model of NASHJS Rodriguez Sanabria0J García Bañuelos1R Escutia Gutiérrez2CA Monraz Méndez3A Santos4J Armendáriz-Borunda5AS Sandoval Rodríguez6Department of Molecular and Genomic Biology, Institute of Molecular Biology in Medicine and Gene Therapy, CUCS, University of Guadalajara, Guadalajara, MexicoDepartment of Molecular and Genomic Biology, Institute of Molecular Biology in Medicine and Gene Therapy, CUCS, University of Guadalajara, Guadalajara, MexicoDepartment of Molecular and Genomic Biology, Institute of Molecular Biology in Medicine and Gene Therapy, CUCS, University of Guadalajara, Guadalajara, MexicoDepartment of Molecular and Genomic Biology, Institute of Molecular Biology in Medicine and Gene Therapy, CUCS, University of Guadalajara, Guadalajara, MexicoFaculty of Medicine and Health Sciences, Tecnológico de Monterrey, Guadalajara Campus, Zapopan, MexicoDepartment of Molecular and Genomic Biology, Institute of Molecular Biology in Medicine and Gene Therapy, CUCS, University of Guadalajara, Guadalajara, Mexico; Faculty of Medicine and Health Sciences, Tecnológico de Monterrey, Guadalajara Campus, Zapopan, MexicoDepartment of Molecular and Genomic Biology, Institute of Molecular Biology in Medicine and Gene Therapy, CUCS, University of Guadalajara, Guadalajara, MexicoIntroduction and Objectives: This study aimed to evaluate how the administration of pirfenidone modifies the expression of JMJD2B in a murine model of NASH. Materials and methods: 4–5-week-old male C57BL/6J mice fed a high-fat diet for 16 weeks. Follow-up was done at 4, 8, 12 and 16 weeks. Serum glucose, animal weight, caloric intake, AST, ALT, TAG, Chol and VLDL were measured. The liver was weighed, as was the epididymal adipose tissue. Masson's trichrome hematoxylin-eosin staining was performed. Dual-channel microarrays were hybridized to the 22,000-gene version of the Mus musculus genome. Analyzed with adjusted P-values of <0.05 and Z-score values of >1.5 and <1.5 considered significant. Quantitative variables were analyzed with ANOVA, Tukey for parametric data, and Kruskal-Wallis for non-parametric data. The trial was approved by the research ethics committee. Results: The animals achieved the body and biochemical parameters that demonstrate the development of NASH. The genes involved in epigenetic processes responsible for the development of NASH (SIRT1, SIRT2, JMJD1B) and, in particular, in JMJD2B; which found to have significantly different between the HFD vs. HFP and HFD vs. ND groups. Discussion: JMJD2B is a histone methylation modulating enzyme, implicated in the development of NASH. In our trial, pirfenidone modulates the expression of JMJD2B, helping the recovery of liver function through epigenetic regulation in a murine model of NASH. Conclusion: Pirfenidone appears to modulate epigenetic factors, supporting recovery from the disease. Funding: The resources used in this study were from the hospital without any additional financing Declaration of interest: The authors declare no potential conflicts of interest.http://www.sciencedirect.com/science/article/pii/S166526812200196X |
| spellingShingle | JS Rodriguez Sanabria J García Bañuelos R Escutia Gutiérrez CA Monraz Méndez A Santos J Armendáriz-Borunda AS Sandoval Rodríguez The administration of pirfenidone modifies the expression of JMJD2B in a murine model of NASH Annals of Hepatology |
| title | The administration of pirfenidone modifies the expression of JMJD2B in a murine model of NASH |
| title_full | The administration of pirfenidone modifies the expression of JMJD2B in a murine model of NASH |
| title_fullStr | The administration of pirfenidone modifies the expression of JMJD2B in a murine model of NASH |
| title_full_unstemmed | The administration of pirfenidone modifies the expression of JMJD2B in a murine model of NASH |
| title_short | The administration of pirfenidone modifies the expression of JMJD2B in a murine model of NASH |
| title_sort | administration of pirfenidone modifies the expression of jmjd2b in a murine model of nash |
| url | http://www.sciencedirect.com/science/article/pii/S166526812200196X |
| work_keys_str_mv | AT jsrodriguezsanabria theadministrationofpirfenidonemodifiestheexpressionofjmjd2binamurinemodelofnash AT jgarciabanuelos theadministrationofpirfenidonemodifiestheexpressionofjmjd2binamurinemodelofnash AT rescutiagutierrez theadministrationofpirfenidonemodifiestheexpressionofjmjd2binamurinemodelofnash AT camonrazmendez theadministrationofpirfenidonemodifiestheexpressionofjmjd2binamurinemodelofnash AT asantos theadministrationofpirfenidonemodifiestheexpressionofjmjd2binamurinemodelofnash AT jarmendarizborunda theadministrationofpirfenidonemodifiestheexpressionofjmjd2binamurinemodelofnash AT assandovalrodriguez theadministrationofpirfenidonemodifiestheexpressionofjmjd2binamurinemodelofnash AT jsrodriguezsanabria administrationofpirfenidonemodifiestheexpressionofjmjd2binamurinemodelofnash AT jgarciabanuelos administrationofpirfenidonemodifiestheexpressionofjmjd2binamurinemodelofnash AT rescutiagutierrez administrationofpirfenidonemodifiestheexpressionofjmjd2binamurinemodelofnash AT camonrazmendez administrationofpirfenidonemodifiestheexpressionofjmjd2binamurinemodelofnash AT asantos administrationofpirfenidonemodifiestheexpressionofjmjd2binamurinemodelofnash AT jarmendarizborunda administrationofpirfenidonemodifiestheexpressionofjmjd2binamurinemodelofnash AT assandovalrodriguez administrationofpirfenidonemodifiestheexpressionofjmjd2binamurinemodelofnash |